CHRS

Handel nachbörslich: 1.10 0.06 +5.77%

Coherus Biosciences Inc (CHRS)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Coherus Biosciences Inc Stock (CHRS) Company Profile

Coherus Biosciences Inc

(650) 649-3530

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CHRS's Discussions on Twitter

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-07-24	Eingeleitet	Citigroup	Buy
2023-05-01	Eingeleitet	Truist	Buy
2023-03-28	Hochstufung	UBS	Neutral → Buy
2022-06-14	Eingeleitet	UBS	Neutral
2022-03-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-07-16	Eingeleitet	BofA Securities	Neutral
2020-04-17	Eingeleitet	SunTrust	Buy
2019-08-13	Eingeleitet	Mizuho	Buy
2019-08-02	Bestätigt	H.C. Wainwright	Buy
2019-08-02	Bestätigt	Maxim Group	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-07	Eingeleitet	H.C. Wainwright	Buy
2018-08-28	Eingeleitet	H.C. Wainwright	Buy
2018-03-09	Bestätigt	Maxim Group	Buy
2017-08-08	Bestätigt	JP Morgan	Overweight
2017-06-13	Bestätigt	Maxim Group	Buy
2017-05-05	Eingeleitet	BMO Capital Markets	Outperform
2016-10-19	Eingeleitet	Robert W. Baird	Outperform
2016-09-07	Eingeleitet	Maxim Group	Buy
2016-07-27	Eingeleitet	Citigroup	Buy
2016-01-20	Eingeleitet	Credit Suisse	Outperform

Alle ansehen

Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten

Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)

Coherus Biosciences Inc (CHRS)

Coherus Biosciences Inc Stock (CHRS) Company Profile

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now - Yahoo Finance

Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges - Investing.com

Junshi wins European approval for cheaper checkpoint blocker - The Pharma Letter

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Insider Monkey

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Yahoo Finance

CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive - Simply Wall St

CHRS (Coherus BioSciences) Debt-to-EBITDA : -10.54 (As of Jun. 2024) - GuruFocus.com

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses - Yahoo Finance

Coherus BioSciences (CHRS) Stock Price, News & Analysis - MarketBeat

HC Wainwright Weighs in on Coherus BioSciences, Inc.'s FY2028 Earnings (NASDAQ:CHRS) - MarketBeat

Coherus shares stumble on supply issue - The Pharma Letter

HC Wainwright Comments on Coherus BioSciences, Inc.'s FY2024 Earnings (NASDAQ:CHRS) - MarketBeat

Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Australia

Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St

Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Canada

Baird maintains Coherus outperform stock rating on recent supply hiccup - Investing.com

Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat

Coherus BioSciences faces UDENYCA supply disruption - Investing.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Downgraded to "Hold" at StockNews.com - MarketBeat

Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 6.0% in August - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Upgraded to Buy by StockNews.com - MarketBeat

CHRS (Coherus BioSciences) Enterprise Value : $254.6 Mil (As of Aug. 19, 2024) - GuruFocus.com

CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com

CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com UK

CHRS (Coherus BioSciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com

UBS Downgrades Coherus BioSciences (CHRS) - MSN

UBS cuts Coherus to neutral, cites limited growth opportunities - MSN

Coherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by UBS Group - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Downgraded by UBS Group - Defense World

UBS cuts Coherus shares target amid concerns over future revenue growth - Investing.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Evaluating Coherus BioSciences: UDENYCA’s Sucess And LOQTORZI’s Prospects (NASDAQ:CHRS) - Seeking Alpha

Vanguard Group Inc. Has $24.09 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript - Seeking Alpha

Coherus BioSciences: Q2 Earnings Snapshot - CTPost

A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element - BioCentury

Coherus BioSciences: Q2 Earnings Snapshot - Houston Chronicle

Coherus BioSciences: Q2 Earnings Snapshot - San Antonio Express-News

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - MSN

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance

Coherus Biosciences Appoints Bryan McMichael as CFO - TipRanks

Coherus BioSciences: Q2 Earnings Snapshot - The Bakersfield Californian

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S - Simply Wall St

Coherus BioSciences (CHRS) to Release Earnings on Thursday - Defense World

Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CHRS